Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

Capricor Therapeutics (NASDAQ:CAPR) had its price objective upped by Cantor Fitzgerald from $25.00 to $30.00 in a research note released on Thursday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Several other research firms have also recently weighed in on CAPR. Oppenheimer reissued an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group increased their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, Capricor Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $34.50.

Capricor Therapeutics Price Performance

CAPR stock opened at $18.61 on Thursday. The stock has a market cap of $845.01 million, a price-to-earnings ratio of -17.56 and a beta of 4.00. The company has a fifty day moving average price of $15.21 and a two-hundred day moving average price of $8.50. Capricor Therapeutics has a one year low of $2.87 and a one year high of $23.40.

Insider Buying and Selling at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics during the 1st quarter worth $40,000. Main Street Financial Solutions LLC lifted its holdings in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Capricor Therapeutics in the third quarter worth about $133,000. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at approximately $147,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $161,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.